{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-116049","form_type":"8-K","ticker":"LIMN","cik":"0001971387","company_name":"Liminatus Pharma, Inc.","filed_at":"2025-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.181128+00:00","generated_at":"2026-05-16T17:04:48.703551+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liminatus Pharma receives Nasdaq delisting notices for failing MVLS and MVPHS rules","bullets":["Notices dated Nov 19, 2025: MVLS below $50M and MVPHS below $15M for 30 consecutive business days.","Company also fails alternative standard under Rule 5450(b)(3)(A) (total assets/revenue each <$50M).","180-day compliance period until May 18, 2026 to regain compliance; stock continues trading under LIMN.","If not compliant by deadline, Nasdaq will issue delisting notice; Company may appeal or transfer to Capital Market.","Management working to regain compliance but no assurance of success."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-116049","json":"https://secwatch.observer/filing/0001104659-25-116049.json","markdown":"https://secwatch.observer/filing/0001104659-25-116049.md","text":"https://secwatch.observer/filing/0001104659-25-116049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/0001104659-25-116049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/tm2532232d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:04:48.703551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"222d5aa2e2438499aa674f3305c64fca95b1c097","claim":"Liminatus Pharma, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).","evidence_excerpt":"November 19, 2025, Liminatus Pharma, Inc. (the “Company”) received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value of Listed Securities (MVLS) of $50,000,000 (the “MVLS Rule”), based upon a review of the Company’s MVLS for the last 30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000 (","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/0001104659-25-116049-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-063806","ticker":"ILLR","company_name":"Triller Group Inc.","filed_at":"2026-06-02T12:26:59+00:00","headline":"Triller gets Nasdaq bid-price exception until June 30, 2026","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063806","json":"https://secwatch.observer/filing/0001213900-26-063806.json","markdown":"https://secwatch.observer/filing/0001213900-26-063806.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/ea0292925-8k_triller.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"November 19, 2025, Liminatus Pharma, Inc. (the\n“Company”) received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that\nthe Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value\nof Listed Securities (MVLS) of $50,000,000 (the “MVLS Rule”), based upon a review of the Company’s MVLS for the last\n30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly\nHeld Shares (MVPHS) of $15,000,000 (","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/0001104659-25-116049-index.htm","comparable_excerpt":"May 29, 2026, the Nasdaq Hearings Panel (the\n“Panel”) notified Triller Group Inc. (“Triller” or the “Company”) that the Panel determined to grant\nTriller an exception to the Listing Rules of The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) until June 30,\n2026 in order to regain compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on April 24, 2026, following\na successful appeal by the Company to the Nasdaq Stock Market Listing and Hearing Review Council (the “Listing Council”) which\nmodified a previous December 26, 2025 decision by a Nasdaq Hearings Panel","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm"}},{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"November 19, 2025, Liminatus Pharma, Inc. (the\n“Company”) received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that\nthe Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value\nof Listed Securities (MVLS) of $50,000,000 (the “MVLS Rule”), based upon a review of the Company’s MVLS for the last\n30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly\nHeld Shares (MVPHS) of $15,000,000 (","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/0001104659-25-116049-index.htm","comparable_excerpt":"May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm"}},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"November 19, 2025, Liminatus Pharma, Inc. (the\n“Company”) received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that\nthe Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value\nof Listed Securities (MVLS) of $50,000,000 (the “MVLS Rule”), based upon a review of the Company’s MVLS for the last\n30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly\nHeld Shares (MVPHS) of $15,000,000 (","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/0001104659-25-116049-index.htm","comparable_excerpt":"May 27, 2026, Actinium Pharmaceuticals, Inc.\n(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating\nthat the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company\nGuide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more\nif it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,\n2026, the Company reported stockholders’ equity of approximately","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm"}},{"accession":"0001683168-26-004399","ticker":"CSAI","company_name":"CLOUDASTRUCTURE, INC.","filed_at":"2026-05-29T21:09:11+00:00","headline":"Cloudastructure receives Nasdaq delinquency notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004399","json":"https://secwatch.observer/filing/0001683168-26-004399.json","markdown":"https://secwatch.observer/filing/0001683168-26-004399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/cloud_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"November 19, 2025, Liminatus Pharma, Inc. (the\n“Company”) received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that\nthe Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value\nof Listed Securities (MVLS) of $50,000,000 (the “MVLS Rule”), based upon a review of the Company’s MVLS for the last\n30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly\nHeld Shares (MVPHS) of $15,000,000 (","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/0001104659-25-116049-index.htm","comparable_excerpt":"May 26, 2026, Cloudastructure,\nInc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq\nStock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for\nthe period ended March 31, 2026 (“Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which\nrequires timely filing of all required periodic financial reports with the Securities and Exchange Commission. The Company requires additional\ntime to review and confirm the accounting treatment for its outstand","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm"}},{"accession":"0001193805-26-000723","ticker":"GURE","company_name":"GULF RESOURCES, INC.","filed_at":"2026-05-29T20:45:30+00:00","headline":"Gulf Resources receives Nasdaq delisting notice for late Q1 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000723","json":"https://secwatch.observer/filing/0001193805-26-000723.json","markdown":"https://secwatch.observer/filing/0001193805-26-000723.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/0001193805-26-000723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/e665526_8k-gulfresources.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"November 19, 2025, Liminatus Pharma, Inc. (the\n“Company”) received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that\nthe Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value\nof Listed Securities (MVLS) of $50,000,000 (the “MVLS Rule”), based upon a review of the Company’s MVLS for the last\n30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly\nHeld Shares (MVPHS) of $15,000,000 (","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/0001104659-25-116049-index.htm","comparable_excerpt":"May 26, 2026, Gulf Resources\n(the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq\nStock Market LLC (“Nasdaq”), indicating that, as a result of not having timely filed its quarterly report on Form 10-Q for\nthe quarter ended March 31, 2026 (the “Form 10-Q”), and the Company remains delinquent in filing its annual report on Form\n10-K for the year ended December 31, 2025 (the “Initial Delinquent Filing”), the Company is in non-compliance with Nasdaq\nListing Rule 5250(c)(1), which requires timely filing all required periodic financial reports wit","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/0001193805-26-000723-index.htm"}},{"accession":"0001654954-26-005548","ticker":"ONFO","company_name":"Onfolio Holdings, Inc","filed_at":"2026-05-29T20:30:53+00:00","headline":"Onfolio receives Nasdaq delisting notice for insufficient equity ($1.22M vs $2.5M min)","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-26-005548","json":"https://secwatch.observer/filing/0001654954-26-005548.json","markdown":"https://secwatch.observer/filing/0001654954-26-005548.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1825452/000165495426005548/0001654954-26-005548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1825452/000165495426005548/onfo_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"November 19, 2025, Liminatus Pharma, Inc. (the\n“Company”) received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that\nthe Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value\nof Listed Securities (MVLS) of $50,000,000 (the “MVLS Rule”), based upon a review of the Company’s MVLS for the last\n30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly\nHeld Shares (MVPHS) of $15,000,000 (","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/0001104659-25-116049-index.htm","comparable_excerpt":"May 26, 2026, Onfolio Holdings Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice states that the Company’s Quarterly Report on Form 10-Q for the for the period ended March 31, 2026 reported stockholders’ equity of $1,216,603. As of the date of the Notice","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1825452/000165495426005548/0001654954-26-005548-index.htm"}},{"accession":"0001213900-26-062172","ticker":"RR","company_name":"RICHTECH ROBOTICS INC.","filed_at":"2026-05-28T20:49:32+00:00","headline":"Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062172","json":"https://secwatch.observer/filing/0001213900-26-062172.json","markdown":"https://secwatch.observer/filing/0001213900-26-062172.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/0001213900-26-062172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/ea0292546-8k_richtech.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"November 19, 2025, Liminatus Pharma, Inc. (the\n“Company”) received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that\nthe Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value\nof Listed Securities (MVLS) of $50,000,000 (the “MVLS Rule”), based upon a review of the Company’s MVLS for the last\n30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly\nHeld Shares (MVPHS) of $15,000,000 (","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/0001104659-25-116049-index.htm","comparable_excerpt":"May 22, 2026, Richtech\n Robotics Inc., a Nevada corporation (the “ Company ”) received a notice (the “ Notice ”) from the Listing\n Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company is not in compliance\n with Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”), because it has not timely filed its Quarterly Report on Form 10-Q\n for the period ended March 31, 2026 (the “ Form 10-Q ”) with the U.S. Securities and Exchange Commission (the “ SEC ”). The\n Rule requires listed companies to timely file all required periodic financial reports with the SEC. The Com","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/0001213900-26-062172-index.htm"}},{"accession":"0001493152-26-025629","ticker":"CDT","company_name":"CDT Equity Inc.","filed_at":"2026-05-28T20:30:30+00:00","headline":"CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025629","json":"https://secwatch.observer/filing/0001493152-26-025629.json","markdown":"https://secwatch.observer/filing/0001493152-26-025629.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"November 19, 2025, Liminatus Pharma, Inc. (the\n“Company”) received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that\nthe Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value\nof Listed Securities (MVLS) of $50,000,000 (the “MVLS Rule”), based upon a review of the Company’s MVLS for the last\n30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly\nHeld Shares (MVPHS) of $15,000,000 (","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/0001104659-25-116049-index.htm","comparable_excerpt":"May 21, 2026, CDT Equity Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Listing\nQualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with\nNasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”) because the Company did not file its Quarterly Report\non Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”) in a timely manner, as required for continued\nlisting on The Nasdaq Capital Market. The Notice has no immediate effect on the listing or trading of the Company’s","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}